- Home
- QQQX vs IMTX Comparison
QQQX vs IMTX Comparison
Compare QQQX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QQQX | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QQQX | IMTX |
|---|---|---|
| Price | $29.34 | $10.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 148.4K | ★ 341.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.64 | $3.94 |
| 52 Week High | $29.38 | $12.41 |
Technical Indicators
Market Signals| Indicator | QQQX | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 60.66 |
| Support Level | $27.08 | $9.61 |
| Resistance Level | N/A | $11.30 |
| Average True Range (ATR) | 0.51 | 0.47 |
| MACD | 0.28 | 0.11 |
| Stochastic Oscillator | 93.96 | 85.75 |
Price Performance
Historical ComparisonAbout QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets (as defined below) in a diversified equity portfolio made up of securities comprising the S&P 500 Index (or securities that have economic characteristics that are similar to those securities comprising the S&P 500 Index) that seeks to substantially replicate price movements of the S&P 500 Index and is designed to support the Fund's option strategy.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.